|
Immune checkpoint inhibitor-based therapy Clinical Trials
1 actively recruiting trial
Also known as: Atezolizumab plus bevacizumab, Durvalumab plus tremelimumab, Nivolumab
Pipeline
Phase 2: 1
Top Sponsors
- Samsung Medical Center1
Indications
- Radiotherapy-Induced Immune Priming1
- Liver Disease1
- Hepatocellular Carcinoma (HCC)1
- Immunotherapy1
- Liver Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.